ID: ALA5202627

Max Phase: Preclinical

Molecular Formula: C43H55ClN6O5

Molecular Weight: 771.40

Associated Items:

Representations

Canonical SMILES:  CN(C(=O)C1CCN(C(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](CCc2ccccc2)C(=O)N[C@@H]2CCCc3ccccc32)CC1)c1ccc(Cl)cc1

Standard InChI:  InChI=1S/C43H55ClN6O5/c1-43(2,3)28-45-38(51)27-37(48-42(55)50-25-23-31(24-26-50)41(54)49(4)33-20-18-32(44)19-21-33)40(53)47-36(22-17-29-11-6-5-7-12-29)39(52)46-35-16-10-14-30-13-8-9-15-34(30)35/h5-9,11-13,15,18-21,31,35-37H,10,14,16-17,22-28H2,1-4H3,(H,45,51)(H,46,52)(H,47,53)(H,48,55)/t35-,36+,37+/m1/s1

Standard InChI Key:  QTRVEQUUYYTPEO-BOALQFNTSA-N

Associated Targets(Human)

20S proteasome 530 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RPMI-8226 44974 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MM1.S 1111 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MV4-11 7307 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 771.40Molecular Weight (Monoisotopic): 770.3922AlogP: 5.96#Rotatable Bonds: 13
Polar Surface Area: 139.95Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 4#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.56CX Basic pKa: CX LogP: 5.42CX LogD: 5.42
Aromatic Rings: 3Heavy Atoms: 55QED Weighted: 0.17Np Likeness Score: -1.00

References

1. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source